ANIP - ANI Pharmaceuticals GAAP EPS of $0.54 beats by $0.68 revenue of $60.9M beats by $4.6M

ANI Pharmaceuticals press release (NASDAQ:ANIP): Q4 GAAP EPS of $0.54 beats by $0.68. Revenue of $60.9M (+6.3% Y/Y) beats by $4.6M. Cash and cash equivalents were $100.3 million, net accounts receivable was $128.5 million, and face value of debt was $300.0 million as of December 31, 2021. Guidance 2022:  Net Revenues of between $260.0 million and $275.0 million vs consensus of $301.70M representing approximately 20% to 27% growth as compared to 2021. Adjusted non-GAAP EBITDA of between $70.0 million and $75.0 million, representing 8% to 16% growth as compared to 2021

For further details see:

ANI Pharmaceuticals GAAP EPS of $0.54 beats by $0.68, revenue of $60.9M beats by $4.6M